Replies to post #298508 on Avid Bioservices Inc (CDMO)

[horselover45]

It will be interesting to see how this plays out.
Back in my younger days when I used to play a lot of chess there was phrase that we used--The end game. Sometimes these end games def don't turn as some people keep forecasting.

[biopharm]

Hmmmm....quite a coincidence or not....but this mention of "Peregrine" below was funded by Sandia


Peregrine RNA-Seq library

Peregrine
A rapid and unbiased method to produce strand-specific RNA-Seq libraries from small quantities of starting material
Stanley A. Langevin, Zachary W. Bent, [...], and Steven S. Branda

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710357/

Very interesting puzzle piece here....brings us back to Ayer Capital Management (Dr Jay Venkatesan and Pieter Boulhower ..)

July 2015 Dr Venkatesan joins Alpine

http://www.businesswire.com/news/home/20150713005408/en/Dr.-Jay-Venkatesan-Joins-Alpine-BioVentures-Managing#.VaOo8SizzDc

http://www.alpinebioventures.com/team/

Now...Alpine Biosciences acquired by Cascadian Therapeutics in August 2014 ...but read below...they licensed tech from Sandia National Labs!! ....and Sandia just had the Peregrine RNA sequence library!

We founded Alpine Biosciences in 2012 to develop "protocells", a unique nanoparticle platform technology licensed from University of Mexico and Sandia National Labs....

http://www.alpinebioventures.com/portfolio/

.....Peregrine what is it you have not been able to tell us and these are solid puzzle pieces. You telling me Dr Venkatesan with Ayer Capital mgmt....sells or forced to sell PPHM and now lands where Alpine with ties to Sandia Nation Labs that were researching Peregrine RNA proteins....??

[biopharm]

Long list of Stafford's and friends and we must also check all Honeywell International Inc links where Susan S Stafford has ties ....a chemist.....and seems like Richard Sinise (chemist) of KCM builds the trend that chemists have strong links to PS Targeting knowledge

I just wanted to make sure my Honeywell Internation links lead back to the same John Stafford III of Ronin Capital Management and group, because this does not make sense why Ronin group wants to halt PS Targeting activities, especially after Dr Jedd Wolchok has found it can reduce off target TOXICITIES

We start with John Stafford exec Bio below and notice board member of

Other Affiliations
Stafford
The University of Chicago
Aware, Inc.
Xencor, Inc.

Background
Mr. John S. Stafford, III serves as the Chief Executive Officer of Ronin Capital, LLC. Mr. Stafford served as the Managing Director, Chairman and Chief Executive Officer at Stafford Trading, Inc. from 1996 to 2001. His venture capital activities consisted of investments in over 40 companies and he serves as a Board Member on several of these companies, including Clinical Micro Sensors, Inc., and All Optical Networks, Inc. Mr. Stafford has been a Director of Aware Inc. since January 5, 2011. He served as a Director of Xencor, Inc. since October 1997 until January 5, 2016. Mr. Stafford attended The University of Chicago.
Collapse Detail

https://www.bloomberg.com/research/stocks/private/person.asp?personId=29896543&privcapId=25755224

Summary
Mr. John S. Stafford, III, is Independent Director at Aware, Inc. (Massachusetts), Founder, President & Chief Executive Officer at Ronin Capital LLC, and Founder at Zen Investments LLC.

He is on the Board of Directors at Aware, Inc. (Massachusetts) and Xencor, Inc.

He co-founded Ronin Capital in 2001.

Mr. Stafford was previously employed at TPG Global and RJS Global.

Mr. Stafford received his undergraduate degree from the University of Chicago.


Current positions of John S. Stafford III
Name Title Since
Ronin Capital LLC Founder, President & Chief Executive Officer 2001
Aware, Inc.
(Software) Independent Director 2011
Clinical Micro Sensors, Inc. Director -
All Optical Networks, Inc. Director -
Chicago Mercantile Exchange, Inc. Member -
Chicago Board Options Exchange, Inc. Member -
Chicago Board of Trade Member -
Zen Investments LLC Founder


John S. Stafford III : Connections
CME Group Inc
Aware, Inc.
WEC Energy Group Inc
International Monetary Fund
Chicago Board of Trade
Gerdes Huff Investments
Civic Committee of the Commercial Club of Chicago
The Commercial Club of Chicago
Northwestern Memorial Hospital
MEI, Inc.
World Federation of Exchanges
Millstreet Capital Management LLC
Chicago Mercantile Exchange, Inc.
Royal Pet Supplies, Inc.
Unistar Financial Service Corp.
Quarry Capital Management LLC
Chicago Board Options Exchange, Inc.
Pursuant Health, Inc.
Navy Pier, Inc.
Friesland Farms LLC

http://www.4-traders.com/business-leaders/John-Stafford-06CH6Z-E/biography/

Prior to joining Ronin Capital LLC, Stafford was the managing director of Stafford Trading from 1996 - 2001. The company was involved in proprietary trading operations and venture capital investments. Stafford Trading was acquired by TD Options in 2001.[3]

He also sits on the board of several companies including Clinical Micro Sensors, Inc., All Optical Networks, Inc. and sat on the board of Xencor for 18 years before resigning in 2016.[4] He was the lead advisor to Xencor and at one time owned 25% of the company's stock.

He is a strategic advisor to OCA Ventures.[5][6][7]

Ronin is an avid golfer, with a reported 8 handicap, who has participated in the Pebble Beach Pro-Am.[8]

http://www.marketswiki.com/wiki/John_S._Stafford_III

_________

Now to back up to Honeywell ....we have a relative there at Honeywell (Honeywell also taking over Sandia National Labs...)

John S Stafford
Zodiac Sign
Scorpio
Gender
Male
Professional Status
Board Member at Aware Inc

Age

John S Stafford is in his 70s
John Has Lived In

Indian Wells, CA
Chicago, IL
Fort Lauderdale, FL
John's Relatives

James Stafford
Susan Stafford

https://www.google.com/amp/s/www.intelius.com/people/John-Stafford/Indian%20Wells-CA/06HKTN5K8X6

Now if we click on Susan Stafford above we find she works at Honeywell and why am I being informed by Ronin group to Halt PS Targeting, when I see nothing but progress in the Labs of Dr Jedd Wolchok as evident by 2017 AACR poster #1651 that North4000 has made very clear....so is there an agenda within Ronin group?

I dont know but we all must ask Ronin group to explain and I want to be made aware if John Stafford or any involved in that group has knowledge that Peregrine, PS Targeting is worth more than they are letting investors know and IF SO...is that defrauding current shareholders if they sell and believe John Stafford / Ronin group?

I am sure Ronin group MUST NOT be upset with my rounds of question because they are here for an investment as they initially told us and I am doing simple landscaping due diligence that should make all wonder what connections are out there that we have not been informed of....and WHY did Sandia National Labs use "Peregrine.." in their RNA research when we all know BIOMARKERS are exactly DNA to RNA to protein and coincidence ....or not ???

Susan S Stafford is in her 50s
Susan Has Lived In

Lake Forest, IL
Morris Plains, NJ
Incline Village, NV

Susan's Relatives

James Stafford
John Stafford


Susan S Stafford
Zodiac Sign
Capricorn
Gender
Female
Professional Status
PM Manager at Honeywell International Inc

https://www.intelius.com/people/Susan-Stafford/Lake%20Forest-IL/0841VH4B9KD

[biopharm]

Microbial signatures bring Biomarkers via PS Targeting

If we analyze all authors and all research published and how fast we are moving towards Biomarkers ....you shall notice the Sandia National Labs funded Peregrine study may be very relevant to PS Targeting and how it opens the doors to massive data that will lead to astronomical biomarkers data

Peregrine RNA-Seq library

Stanley A. Langevin, † Zachary W. Bent, † Owen D. Solberg, Deanna J. Curtis, Pamela D. Lane, Kelly P. Williams, Joseph S. Schoeniger, Anupama Sinha, Todd W. Lane, and Steven S. Branda*
Biotechnology and Bioengineering; Sandia National Laboratories; Livermore, CA USA
†These authors contributed equally.
*Correspondence to: Steven S. Branda, Email: vog.aidnas@adnarbs

Received 2012 Dec 20;
Revised 2013 Feb 15;
Accepted 2013 Mar 13.

Peregrine
A rapid and unbiased method to produce strand-specific RNA-Seq libraries from small quantities of starting material
Stanley A. Langevin, Zachary W. Bent, [...], and Steven S. Branda

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710357/

..Early_nasopharyngeal_microbial_signature_associated_with_severe_influenza_in_children_a_retrospective_pilot_study

Early nasopharyngeal microbial signature associated with severe influenza in children: a retrospective pilot study

Article in Journal of General Virology · September 2017
DOI: 10.1099/jgv.0.000920

Stanley Langevin

Maxime Pichon at University Hospital of Lyon, France
Maxime Pichon
15.01University Hospital of Lyon, France

Elise Smith at University of Washington Seattle
Elise Smith
12.58University of Washington Seattle

Juliet Morrison
Not on ResearchGate

Zachary Bent
Not on ResearchGate

Richard Green
Not on ResearchGate

Kristi Leigh Barker at NanoString Technologies
Kristi Leigh Barker
25.76NanoString Technologies

Owen Solberg
Not on ResearchGate
Yves Gillet at Centre Hospitalier Universitaire de Lyon
Yves Gillet
30.75Centre Hospitalier Universitaire de Lyon

Etienne Javouhey
Not on ResearchGate

Bruno Lina at Claude Bernard University Lyon 1
Bruno Lina
45.33Claude Bernard University Lyon 1

Michael G. Katze
Not on ResearchGate

Laurence Josset at University of Washington Seattle
Laurence Josset
29.95University of Washington Seattle


Abstract
A few studies have highlighted the importance of the respiratory microbiome in modulating the frequency and outcome of viral respiratory infections. However, there are insufficient data on the use of microbial signatures as prognostic biomarkers to predict respiratory disease outcomes. In this study, we aimed to evaluate whether specific bacterial community compositions in the nasopharynx of children at the time of hospitalization are associated with different influenza clinical outcomes. We utilized retrospective nasopharyngeal (NP) samples (n=36) collected at the time of hospital arrival from children who were infected with influenza virus and had been symptomatic for less than 2 days. Based on their clinical course, children were classified into two groups: patients with mild influenza, and patients with severe respiratory or neurological complications. We implemented custom 16S rRNA gene sequencing, metagenomic sequencing and computational analysis workflows to classify the bacteria present in NP specimens at the species level. We found that increased bacterial diversity in the nasopharynx of children was strongly associated with influenza severity. In addition, patients with severe influenza had decreased relative abundance of Staphylococcus aureus and increased abundance of Prevotella (including P. melaninogenica), Streptobacillus, Porphyromonas, Granulicatella (including G. elegans), Veillonella (including V. dispar), Fusobacterium and Haemophilus in their nasopharynx. This pilot study provides proof-of-concept data for the use of microbial signatures as prognostic biomarkers of influenza outcomes. Further large prospective cohort studies are needed to refine and validate the performance of such microbial signatures in clinical settings.

https://www.researchgate.net/publication/319481762_Early_nasopharyngeal_microbial_signature_associated_with_severe_influenza_in_children_a_retrospective_pilot_study